COG AALL1521/INCB 18424-269: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (ALL)

      Project: Research project

      Project Details

      StatusFinished
      Effective start/end date12/1/1612/4/19

      Funding

      • Children's Hospital of Philadelphia
      • Incyte Corporation